Phase III Study of Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma.

Trial Profile

Phase III Study of Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Thalidomide (Primary) ; Ethiodized oil; Fluorouracil; Mitomycin; Oxaliplatin
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Apr 2011 Planned End Date changed from 1 Jun 2012 to 1 Apr 2013, according to ClinicalTrials.gov.
    • 20 Apr 2011 Time to progression is now a secondary endpoint not a primary endpoint and inclusion criteria, ECOG score has been changed from 1-2 to 0-2; reported by ClinicalTrials.gov.
    • 01 Jul 2009 Planned end date changed from 1 Jun 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top